MYC amplification/overexpression sensitizes preclinical SCLC models to Aurora kinase inhibitors as well as arginine deprivation (Cardnell et al., 2017; Chalishazar et al., 2019; Mollaoglu et al., 2017). The gene discussed is MYC; the disease is small cell lung carcinoma.